Clinical implications of the concentration of alveolar nitric oxide in non-small cell lung cancer  

作　　者：Xiaodan Chang Hua Liao Lingyan Xie Yuehua Chen Liying Zheng Jianpeng Liang Weiwei Yu Yuexian Wu Yanmei Ye Shuyu Huang Haijin Zhao Shaoxi Cai Hangming Dong 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Chronic Airways Diseases Laboratory,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China [2]School of Nursing,Southern Medical University,Guangzhou,Guangdong 510515,China [3]Department of Respiratory and Critical Care Medicine,The Fifth Affiliated Hospital,Southern Medical University,Guangzhou,Guangdong 510900,China

出　　处：《Chinese Medical Journal》2023年第18期2246-2248,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China(Nos.82170032 and 81970032)

摘　　要：To the Editor:Lung cancer,one of the most common types of tumor,is also the leading cause of cancer death,accounting for an estimated 1.8 million deaths worldwide.Early recognition of lung cancer is critical.It has been established that nitric oxide and its byproducts play a role in pathophysiological processes of lung cancer,such as tumor immunity,inflammation,and lung tumor progression.[1]Exhaled nitric oxide(eNO)concentrations can be measured by non-invasive devices.The alveolar concentration of nitric oxide(CaNO)has been proposed as a marker of distal airway inflammation,but its value in nonsmall cell lung cancer(NSCLC)is unknown.

关 键 词：INFLAMMATION LUNG ALVEOLAR 

分 类 号：R734.2[医药卫生—肿瘤]